Logótipo da Cepheid
Solicitar informação
Localização / Idioma

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Localização / Idioma

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Solicitar informação
Solicitar informação

Xpert® Breast Cancer STRAT4

Order Now
STRAT4 computer generated depiction.

Avaliação por método padronizado de biomarcadores de ARNm de ESR1/PGR/ERBB2/MKi67 de cancro da mama em menos de duas horas

A necessidade

an ill woman listens to a physician
Os resultados do biomarcador ER/PGR/HER2/Ki-67 do cancro da mama têm de ser confiáveis e objetivos
  • Os médicos precisam de avaliações de ER/PGR/HER2/Ki-67 mais fiáveis em tecidos de tumor FFPE.
  • 5% dos resultados de HER2 IHC são equívocos com base nas orientações de classificações recomendadas.1
  • A resolução de resultados de HER2 IHC2+ equívocos com FISH é um desafio.1-4
  • A variabilidade técnica e de observadores podem levar a uma imprecisão de aproximadamente 20% nos resultados ER e PGR.5
  • As pontuações Ki-67 IHC desviam-se devido a uma falta de padronização.6
(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues’ Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.

A solução

a male and a female researchers scanning cepheid test cartridges
Xpert Breast Cancer STRAT4 supports standardized ER/PGR/HER2/Ki‑67 mRNA assessment in less than 2 hours.
  • O Xpert Breast Cancer STRAT4 oferece determinação semiquantitativa de níveis de mRNA de ER/PGR/HER2/Ki-67 em biópsias de cancro da mama invasivo FFPE
    • O gene de referência CYFIP1* é utilizado para padronização de amostras
    • Três controlos incluídos em cada teste
    • O relatório de software permite uma interpretação dos resultados objetiva e fácil
CYFIP1: Proteína 1 citoplasmática de interação com FMR1

O impacto

a smiling female doctor attends an elderly woman
  • Fast, clear, and accurate results by STRAT4 can help laboratories in diverse settings address various challenges with IHC/ISH testing to aid in the clinical evaluation of patients. 6
  • May facilitate a cost-efficient, quick, easy, and quality solution in labs facing challenges with IHC.7-9
  • Enables decentralized testing that doesn’t require a PCR laboratory to support breast cancer testing in low- and middle-income countries. 6.7.9
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.
(7) Marcellin Mugabe, Kenneth E Ho, Deo Ruhangaza, Dan Milner, Belson Rugwizangoga, Victor C Chu, Natalie C Wu, Annaliza Rizo, Jodi M Weidler, Wendy Wong, Michael Bates, Jane E Brock, Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country, American Journal of Clinical Pathology, Volume 156, Issue 5, November 2021, Pages 766–776, https://doi.org/10.1093/ajcp/aqab016
(8) El Aje, R, Naya A, Khoaja A, Zaid Y, Oudghiri M, Weidler J, and Karkouri M. A Study Comparing Immunohistochemistry, Fluorescence in situ hybridization, GeneXpert® Breast Cancer STRAT4 Assay for Determining Hormone Receptor, Human Epidermal Growth Factor Receptor 2, Ki67 Status in Invasive Breast Carcinomain Moroccan women. Progress in Microbes and Molecular Biology. 2023; 6, 1; a0000332. doi: 10.36877/pmmb.a0000332.
(9) Erfani P et al. Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert® mRNA expression assay. Bull World Health Organ 2023;101:10–19 | doi: http://dx.doi.org/10.2471/BLT.22.288800 The Impact The Need The Solution Breast cancer in women is the leading cancer worldwide, with approximately 2.3 million new breast cancer cases every year.

Ligue-se e alcance os melhores resultados

Solicitar informação
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web